

Jakub Fichna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6435858/publications.pdf>

Version: 2024-02-01

308
papers

7,335
citations

71102

41
h-index

98798

67
g-index

318
all docs

318
docs citations

318
times ranked

9174
citing authors

#	ARTICLE	IF	CITATIONS
1	Review article: the role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2014, 387, 605-620.	3.0	288
2	Opioid Receptors and their Ligands. <i>Current Topics in Medicinal Chemistry</i> , 2004, 4, 1-17.	2.1	240
3	The Endomorphin System and Its Evolving Neurophysiological Role. <i>Pharmacological Reviews</i> , 2007, 59, 88-123.	16.0	217
4	The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders. <i>Pharmacological Research</i> , 2021, 172, 105840.	7.1	201
5	Distribution, function and physiological role of melatonin in the lower gut. <i>World Journal of Gastroenterology</i> , 2011, 17, 3888.	3.3	173
6	Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives. <i>Journal of Gastroenterology</i> , 2014, 49, 24-45.	5.1	151
7	Beneficial Effects of Probiotics, Prebiotics, Synbiotics, and Psychobiotics in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1674-1682.	1.9	131
8	Synthesis of Target-Specific Radiolabeled Peptides for Diagnostic Imaging. <i>Bioconjugate Chemistry</i> , 2003, 14, 3-17.	3.6	124
9	LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity. <i>Pharmacological Reports</i> , 2016, 68, 802-808.	3.3	117
10	The role of morphine in regulation of cancer cell growth. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2011, 384, 221-230.	3.0	114
11	Effects of Berberine in the Gastrointestinal Tract – A Review of Actions and Therapeutic Implications. <i>The American Journal of Chinese Medicine</i> , 2014, 42, 1053-1070.	3.8	106
12	Brain-Gut Interactions in IBS. <i>Frontiers in Pharmacology</i> , 2012, 3, 127.	3.5	99
13	A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome. <i>Phytotherapy Research</i> , 2015, 29, 1822-1827.	5.8	96
14	Polyphenols as mitochondria-targeted anticancer drugs. <i>Cancer Letters</i> , 2015, 366, 141-149.	7.2	92
15	Chinese Herbal Medicines in the Treatment of IBD and Colorectal Cancer: A Review. <i>Current Treatment Options in Oncology</i> , 2014, 15, 405-420.	3.0	87
16	Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH). <i>Journal of Crohn's and Colitis</i> , 2014, 8, 998-1009.	1.3	85
17	Enzymatic degradation of endomorphins. <i>Peptides</i> , 2008, 29, 2066-2073.	2.4	84
18	Current overview of extrinsic and intrinsic factors in etiology and progression of inflammatory bowel diseases. <i>Pharmacological Reports</i> , 2014, 66, 766-775.	3.3	81

#	ARTICLE	IF	CITATIONS
19	The Nrf2 in the pathophysiology of the intestine: Molecular mechanisms and therapeutic implications for inflammatory bowel diseases. <i>Pharmacological Research</i> , 2021, 163, 105243.	7.1	81
20	Characterization and distribution of NKD, a receptor for <i>Drosophila</i> tachykinin-related peptide 6. <i>Peptides</i> , 2009, 30, 545-556.	2.4	78
21	Polyunsaturated Fatty Acids and Their Derivatives: Therapeutic Value for Inflammatory, Functional Gastrointestinal Disorders, and Colorectal Cancer. <i>Frontiers in Pharmacology</i> , 2016, 7, 459.	3.5	71
22	Transient Receptor Potential Vanilloid 4 blockade protects against experimental colitis in mice: a new strategy for inflammatory bowel diseases treatment?. <i>Neurogastroenterology and Motility</i> , 2012, 24, e557-60.	3.0	70
23	A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice. <i>Neuropharmacology</i> , 2013, 71, 255-263.	4.1	64
24	Salvinorin A inhibits colonic transit and neurogenic ion transport in mice by activating μ -opioid and cannabinoid receptors. <i>Neurogastroenterology and Motility</i> , 2009, 21, 1326.	3.0	62
25	Salvinorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors*. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1137-1145.	1.9	61
26	Fat-soluble Vitamin Deficiencies and Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 878-889.	2.2	61
27	The mechanisms linking obesity to colon cancer: An overview. <i>Obesity Research and Clinical Practice</i> , 2018, 12, 251-259.	1.8	60
28	Cannabinoids Alleviate Experimentally Induced Intestinal Inflammation by Acting at Central and Peripheral Receptors. <i>PLoS ONE</i> , 2014, 9, e109115.	2.5	59
29	Experimental colitis in mice is attenuated by topical administration of chlorogenic acid. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2015, 388, 643-651.	3.0	58
30	Non-Specific Abdominal Pain and Air Pollution: A Novel Association. <i>PLoS ONE</i> , 2012, 7, e47669.	2.5	57
31	G protein-coupled estrogen receptor and estrogen receptor ligands regulate colonic motility and visceral pain. <i>Neurogastroenterology and Motility</i> , 2017, 29, e13025.	3.0	55
32	Selective inhibition of <i>FAAH</i> produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides. <i>Neurogastroenterology and Motility</i> , 2014, 26, 470-481.	3.0	54
33	Anemia of Chronic Disease and Iron Deficiency Anemia in Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1198-1208.	1.9	54
34	Lactoferrin: an overview of its main functions, immunomodulatory and antimicrobial role, and clinical significance. <i>Critical Reviews in Food Science and Nutrition</i> , 2022, 62, 6016-6033.	10.3	52
35	Antidepressant-Like Effect of Endomorphin-1 and Endomorphin-2 in Mice. <i>Neuropsychopharmacology</i> , 2007, 32, 813-821.	5.4	50
36	Role of Transient Receptor Potential Channels in Intestinal Inflammation and Visceral Pain. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 419-427.	1.9	50

#	ARTICLE	IF	CITATIONS
37	Endomorphin Analogs. <i>Current Medicinal Chemistry</i> , 2007, 14, 3201-3208.	2.4	49
38	Endocannabinoid and Cannabinoid-Like Fatty Acid Amide Levels Correlate with Pain-Related Symptoms in Patients with IBS-D and IBS-C: A Pilot Study. <i>PLoS ONE</i> , 2013, 8, e85073.	2.5	45
39	Opioid peptides in cancer. <i>Cancer and Metastasis Reviews</i> , 2004, 23, 351-366.	5.9	43
40	Common links between metabolic syndrome and inflammatory bowel disease: Current overview and future perspectives. <i>Pharmacological Reports</i> , 2016, 68, 837-846.	3.3	43
41	Development of Opioid Peptide Analogs for Pain Relief. <i>Current Pharmaceutical Design</i> , 2010, 16, 1126-1135.	1.9	42
42	Cannabinoid Receptor Type 1 and mu-Opioid Receptor Polymorphisms Are Associated With Cyclic Vomiting Syndrome. <i>American Journal of Gastroenterology</i> , 2017, 112, 933-939.	0.4	42
43	Enzymatic degradation studies of endomorphin-2 and its analogs containing N-methylated amino acids. <i>Peptides</i> , 2006, 27, 131-135.	2.4	41
44	Berberine Improves Intestinal Motility and Visceral Pain in the Mouse Models Mimicking Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Symptoms in an Opioid-Receptor Dependent Manner. <i>PLoS ONE</i> , 2015, 10, e0145556.	2.5	41
45	Synthesis and Characterization of Potent and Selective μ -Opioid Receptor Antagonists, [Dmt, d-2-Nal4]endomorphin-1 (Antanal-1) and [Dmt1, d-2-Nal4]endomorphin-2 (Antanal-2). <i>Journal of Medicinal Chemistry</i> , 2007, 50, 512-520.	6.4	40
46	Polyphenol extract from evening primrose pomace alleviates experimental colitis after intracolonic and oral administration in mice. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2014, 387, 1069-1078.	3.0	40
47	Triphala: current applications and new perspectives on the treatment of functional gastrointestinal disorders. <i>Chinese Medicine</i> , 2018, 13, 39.	4.0	39
48	Focus on current and future management possibilities in inflammatory bowel disease-related chronic pain. <i>International Journal of Colorectal Disease</i> , 2019, 34, 217-227.	2.2	39
49	Synthesis and biological evaluation of cyclic endomorphin-2 analogs. <i>Peptides</i> , 2010, 31, 339-345.	2.4	38
50	The cannabinoid CB_1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice. <i>Neurogastroenterology and Motility</i> , 2013, 25, e550-9.	3.0	37
51	Synthesis and evaluation of anti-inflammatory properties of silver nanoparticle suspensions in experimental colitis in mice. <i>Chemical Biology and Drug Design</i> , 2017, 89, 538-547.	3.2	37
52	Opioid receptor binding and in vivo antinociceptive activity of position 3-substituted morphiceptin analogs. <i>Biochemical and Biophysical Research Communications</i> , 2004, 320, 531-536.	2.1	35
53	The Influence of Opioids on Urokinase Plasminogen Activator on Protein and mRNA Level in MCF7 Breast Cancer Cell Line. <i>Chemical Biology and Drug Design</i> , 2009, 74, 390-396.	3.2	35
54	Orally available extract from <i>Brassica oleracea</i> var. <i>capitata rubra</i> attenuates experimental colitis in mouse models of inflammatory bowel diseases. <i>Journal of Functional Foods</i> , 2015, 17, 587-599.	3.4	35

#	ARTICLE	IF	CITATIONS
55	Encenicline, an $\alpha 7$ Nicotinic Acetylcholine Receptor Partial Agonist, Reduces Immune Cell Infiltration in the Colon and Improves Experimental Colitis in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 356, 157-169.	2.5	35
56	Free Fatty Acid Receptors as new potential therapeutic target in inflammatory bowel diseases. <i>Pharmacological Research</i> , 2020, 152, 104604.	7.1	35
57	Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 52, 173-179.	4.0	34
58	Expression and physiology of opioid receptors in the gastrointestinal tract. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2016, 23, 3-10.	2.3	34
59	Targeting Histamine Receptors in Irritable Bowel Syndrome: A Critical Appraisal. <i>Journal of Neurogastroenterology and Motility</i> , 2017, 23, 341-348.	2.4	34
60	Correlations between skin lesions induced by anti-tumor necrosis factor- α and selected cytokines in Crohn's disease patients. <i>World Journal of Gastroenterology</i> , 2014, 20, 7019.	3.3	33
61	Fatty acid amide hydrolase (FAAH) inhibitor PF-3845 reduces viability, migration and invasiveness of human colon adenocarcinoma Colo-205 cell line: an in vitro study. <i>Acta Biochimica Polonica</i> , 2017, 64, 519-525.	0.5	33
62	Novel Orally Available Salvinorin A Analog PR-38 Inhibits Gastrointestinal Motility and Reduces Abdominal Pain in Mouse Models Mimicking Irritable Bowel Syndrome. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 350, 69-78.	2.5	31
63	Transient receptor potential vanilloid 4 inhibits mouse colonic motility by activating NO-dependent enteric neurotransmission. <i>Journal of Molecular Medicine</i> , 2015, 93, 1297-1309.	3.9	31
64	Estrogen signaling deregulation related with local immune response modulation in irritable bowel syndrome. <i>Molecular and Cellular Endocrinology</i> , 2018, 471, 89-96.	3.2	31
65	Anti-inflammatory and antinociceptive action of the dimeric enkephalin peptide biphalin in the mouse model of colitis: New potential treatment of abdominal pain associated with inflammatory bowel diseases. <i>Peptides</i> , 2014, 60, 102-106.	2.4	30
66	Current concepts in the pathogenesis of cryptoglandular perianal fistula. <i>Journal of International Medical Research</i> , 2021, 49, 030006052098666.	1.0	30
67	Biological activity of endomorphin and [Dmt1]endomorphin analogs with six-membered proline surrogates in position 2. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 3789-3794.	3.0	29
68	Flavanols from Japanese quince (<i>Chaenomeles japonica</i>) fruit suppress expression of cyclooxygenase-2, metalloproteinase-9, and nuclear factor- κ B in human colon cancer cells. <i>Acta Biochimica Polonica</i> , 2017, 64, 567-576.	0.5	29
69	Sex- and Age-Related Estrogen Signaling Alteration in Inflammatory Bowel Diseases: Modulatory Role of Estrogen Receptors. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3175.	4.1	29
70	G protein-coupled estrogen receptor mediates anti-inflammatory action in Crohn's disease. <i>Scientific Reports</i> , 2019, 9, 6749.	3.3	29
71	Novel orally available salvinorin A analog PR-38 protects against experimental colitis and reduces abdominal pain in mice by interaction with opioid and cannabinoid receptors. <i>Biochemical Pharmacology</i> , 2014, 92, 618-626.	4.4	28
72	Anti-Inflammatory and Antinociceptive Action of an Orally Available Nociceptin Receptor Agonist SCH 221510 in a Mouse Model of Inflammatory Bowel Diseases. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 348, 401-409.	2.5	28

#	ARTICLE	IF	CITATIONS
73	Circadian rhythm abnormalities – Association with the course of inflammatory bowel disease. <i>Pharmacological Reports</i> , 2016, 68, 847-851.	3.3	28
74	Synthesis and biological activity of N-methylated analogs of endomorphin-2. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 6713-6717.	3.0	27
75	Opioid-induced regulation of μ -opioid receptor gene expression in the MCF-7 breast cancer cell line. <i>Biochemistry and Cell Biology</i> , 2008, 86, 217-226.	2.0	27
76	Enhancement of anticancer potential of polyphenols by covalent modifications. <i>Biochemical Pharmacology</i> , 2016, 109, 1-13.	4.4	27
77	Role of glucagon-like peptides in inflammatory bowel diseases – current knowledge and future perspectives. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2019, 392, 1321-1330.	3.0	27
78	Functional comparison of two evolutionary conserved insect neurokinin-like receptors. <i>Peptides</i> , 2007, 28, 103-108.	2.4	26
79	Effect of 2,6-dimethyl-L-tyrosine (Dmt) on pharmacological activity of cyclic endomorphin-2 and morphiceptin analogs. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 6977-6981.	3.0	26
80	Current Overview on Clinical Management of Chronic Constipation. <i>Journal of Clinical Medicine</i> , 2021, 10, 1738.	2.4	26
81	G Protein-Coupled Receptor 30 (GPR30) Expression Pattern in Inflammatory Bowel Disease Patients Suggests its Key Role in the Inflammatory Process. A Preliminary Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 26, 29-35.	0.9	26
82	Characterization of antinociceptive activity of novel endomorphin-2 and morphiceptin analogs modified in the third position. <i>Biochemical Pharmacology</i> , 2005, 69, 179-185.	4.4	25
83	Synthesis and antinociceptive activity of cyclic endomorphin-2 and morphiceptin analogs. <i>Biochemical Pharmacology</i> , 2005, 71, 188-195.	4.4	25
84	Inhibition of proteases as a novel therapeutic strategy in the treatment of metabolic, inflammatory and functional diseases of the gastrointestinal tract. <i>Drug Discovery Today</i> , 2013, 18, 708-715.	6.4	25
85	Novel mixed NOP/MOP agonist BU08070 alleviates pain and inhibits gastrointestinal motility in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms. <i>European Journal of Pharmacology</i> , 2014, 736, 63-69.	3.5	25
86	The influence of lipoic acid on caveolin-1-regulated antioxidative enzymes in the mouse model of acute ulcerative colitis. <i>Biomedicine and Pharmacotherapy</i> , 2016, 84, 470-475.	5.6	25
87	Abnormal cannabidiol attenuates experimental colitis in mice, promotes wound healing and inhibits neutrophil recruitment. <i>Journal of Inflammation</i> , 2016, 13, 21.	3.4	25
88	Novel peptide inhibitor of dipeptidyl peptidase IV (Tyr-Pro-D-Ala-NH ₂) with anti-inflammatory activity in the mouse models of colitis. <i>Peptides</i> , 2018, 108, 34-45.	2.4	25
89	Efficacy and Safety of Serotonin Receptor Ligands in the Treatment of Irritable Bowel Syndrome: A Review. <i>Current Drug Targets</i> , 2018, 19, 1774-1781.	2.1	25
90	Functional Characterization of Opioid Receptor Ligands by Aequorin Luminescence-Based Calcium Assay. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 317, 1150-1154.	2.5	24

#	ARTICLE	IF	CITATIONS
91	<i>In vitro</i> and non-invasive <i>in vivo</i> effects of the cannabinoid CB1 receptor agonist AM841 on gastrointestinal motor function in the rat. <i>Neurogastroenterology and Motility</i> , 2015, 27, 1721-1735.	3.0	24
92	New Peptide Inhibitor of Dipeptidyl Peptidase IV, EMDB-1 Extends the Half-Life of GLP-2 and Attenuates Colitis in Mice after Topical Administration. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 363, 92-103.	2.5	24
93	Chitinases and Chitinase-Like Proteins as Therapeutic Targets in Inflammatory Diseases, with a Special Focus on Inflammatory Bowel Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6966.	4.1	24
94	Synthesis and Biological Activity of Endomorphin-2 Analogs Incorporating Piperidine-2, 3- or 4-Carboxylic Acids Instead of Proline in Position 2. <i>Chemical Biology and Drug Design</i> , 2008, 72, 91-94.	3.2	23
95	The Anti-Inflammatory Effect and Intestinal Barrier Protection of HU210 Differentially Depend on TLR4 Signaling in Dextran Sulfate Sodium-Induced Murine Colitis. <i>Digestive Diseases and Sciences</i> , 2017, 62, 372-386.	2.3	23
96	Walnut Oil Alleviates Intestinal Inflammation and Restores Intestinal Barrier Function in Mice. <i>Nutrients</i> , 2020, 12, 1302.	4.1	23
97	Opioids in Cancer Development, Progression and Metastasis: Focus on Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2020, 21, 6.	3.0	23
98	Pharmacological and dietary factors in prevention of colorectal cancer. <i>Journal of Physiology and Pharmacology</i> , 2018, 69, .	1.1	23
99	Role of environmental pollution in irritable bowel syndrome. <i>World Journal of Gastroenterology</i> , 2015, 21, 11371.	3.3	23
100	Tenapanor hydrochloride for the treatment of constipation-predominant irritable bowel syndrome. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1093-1099.	4.1	22
101	Systemic administration of serotonin exacerbates abdominal pain and colitis via interaction with the endocannabinoid system. <i>Biochemical Pharmacology</i> , 2019, 161, 37-51.	4.4	22
102	Chemerin in immune response and gastrointestinal pathophysiology. <i>Clinica Chimica Acta</i> , 2020, 504, 146-153.	1.1	22
103	Gold (III) Derivatives in Colon Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 724.	4.1	22
104	Inhibition of trigemino-hypoglossal reflex in rats by oxytocin is mediated by μ and δ opioid receptors. <i>Brain Research</i> , 2005, 1035, 67-72.	2.2	21
105	Effectiveness and therapeutic value of phytochemicals in acute pancreatitis: A review. <i>Pancreatology</i> , 2019, 19, 481-487.	1.1	21
106	Silver nanoparticles based on blackcurrant extract show potent anti-inflammatory effect <i>in vitro</i> and in DSS-induced colitis in mice. <i>International Journal of Pharmaceutics</i> , 2020, 585, 119549.	5.2	21
107	New Trends in Liposome-based Drug Delivery in Colorectal Cancer. <i>Mini-Reviews in Medicinal Chemistry</i> , 2018, 19, 3-11.	2.4	21
108	Preventing Bacterial Translocation in Patients with Leaky Gut Syndrome: Nutrition and Pharmacological Treatment Options. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3204.	4.1	21

#	ARTICLE	IF	CITATIONS
109	Synthesis and biological evaluation of novel peripherally active morphiceptin analogs. <i>Peptides</i> , 2010, 31, 1617-1624.	2.4	20
110	Orally administered novel cyclic pentapeptide P-317 alleviates symptoms of diarrhoea-predominant irritable bowel syndrome. <i>Journal of Pharmacy and Pharmacology</i> , 2015, 67, 244-254.	2.4	20
111	Inflammation-associated changes in DOR expression and function in the mouse colon. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, G544-G559.	3.4	20
112	Nociceptin / Orphanin FQ (NOP) Receptors as Novel Potential Target in the Treatment of Gastrointestinal Diseases. <i>Current Drug Targets</i> , 2013, 14, 1203-1209.	2.1	20
113	Calea zacatechichi dichloromethane extract exhibits antidiarrheal and antinociceptive effects in mouse models mimicking irritable bowel syndrome. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2015, 388, 1069-1077.	3.0	19
114	Anti-inflammatory effect of dual nociceptin and opioid receptor agonist, BU08070, in experimental colitis in mice. <i>European Journal of Pharmacology</i> , 2015, 765, 582-590.	3.5	19
115	Evaluation of anti-inflammatory effect of silver-coated glass beads in mice with experimentally induced colitis as a new type of treatment in inflammatory bowel disease. <i>Pharmacological Reports</i> , 2017, 69, 386-392.	3.3	19
116	One step ahead: miRNA-34 in colon cancer-future diagnostic and therapeutic tool?. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 132, 1-8.	4.4	19
117	Management of pain in colorectal cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103122.	4.4	19
118	Brain-derived neurotrophic factor is elevated in the blood serum of Crohn's disease patients, but is not influenced by anti-TNF α treatment. A pilot study. <i>Neurogastroenterology and Motility</i> , 2021, 33, e13978.	3.0	19
119	Selective natural kappa opioid and cannabinoid receptor agonists with a potential role in the treatment of gastrointestinal dysfunction. <i>Drug News and Perspectives</i> , 2009, 22, 383.	1.5	19
120	Anti-inflammatory action of a novel orally available peptide 317 in mouse models of inflammatory bowel diseases. <i>Pharmacological Reports</i> , 2014, 66, 741-750.	3.3	18
121	Melatonin, but not melatonin receptor agonists Neu-P11 and Neu-P67, attenuates TNBS-induced colitis in mice. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2016, 389, 511-519.	3.0	18
122	Antinociceptive effects of novel melatonin receptor agonists in mouse models of abdominal pain. <i>World Journal of Gastroenterology</i> , 2014, 20, 1298.	3.3	18
123	Design, Synthesis and Pharmacological Characterization of Endomorphin Analogues with Non-Cyclic Amino Acid Residues in Position 2. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2010, 106, 106-113.	2.5	17
124	Anti-inflammatory effect of novel analogs of natural enkephalinase inhibitors in a mouse model of experimental colitis. <i>Future Medicinal Chemistry</i> , 2016, 8, 2231-2243.	2.3	17
125	Systemic Administration of Sialorphan Attenuates Experimental Colitis in Mice via Interaction With Mu and Kappa Opioid Receptors. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 988-998.	1.3	17
126	Future Treatment of Constipation-associated Disorders: Role of Relamorelin and Other Ghrelin Receptor Agonists. <i>Journal of Neurogastroenterology and Motility</i> , 2017, 23, 171-179.	2.4	17

#	ARTICLE	IF	CITATIONS
127	New insights into molecular pathways in colorectal cancer: Adiponectin, interleukin-6 and opioid signaling. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188460.	7.4	17
128	In vitro Characterization of Novel Peptide Inhibitors of Endomorphin-degrading Enzymes in the Rat Brain. <i>Chemical Biology and Drug Design</i> , 2006, 68, 173-175.	3.2	16
129	Activation of the endogenous nociceptin system by selective nociceptin receptor agonist <sc>SCH</sc> 221510 produces antitransit and antinociceptive effect: a novel strategy for treatment of diarrheaâ€predominant <sc>IBS</sc>. <i>Neurogastroenterology and Motility</i> , 2014, 26, 1539-1550.	3.0	16
130	Salvinorin <sc>A</sc> analogues <sc>PR</sc>â€37 and <sc>PR</sc>â€38 attenuate compound 48/80â€induced itch responses in mice. <i>British Journal of Pharmacology</i> , 2015, 172, 4331-4341.	5.4	16
131	Novel investigational drugs for constipation-predominant irritable bowel syndrome: a review. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 275-286.	4.1	16
132	Mean Platelet Volume in Crohnâ€™s Disease Patients Predicts Sustained Response to a 52-Week Infliximab Therapy: A Pilot Study. <i>Digestive Diseases and Sciences</i> , 2016, 61, 542-549.	2.3	16
133	Serum Cyclophilin A Correlates with Increased Tissue MMP-9 in Patients with Ulcerative Colitis, but Not with Crohnâ€™s Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1511-1517.	2.3	16
134	Bile acids and FXR in functional gastrointestinal disorders. <i>Digestive and Liver Disease</i> , 2018, 50, 795-803.	0.9	16
135	Supplementation of Bovine Colostrum in Inflammatory Bowel Disease: Benefits and Contraindications. <i>Advances in Nutrition</i> , 2021, 12, 533-545.	6.4	16
136	The role of fatty acids in Crohn's disease pathophysiology â€“ An overview. <i>Molecular and Cellular Endocrinology</i> , 2021, 538, 111448.	3.2	16
137	Ischemic Colitis: Current Diagnosis and Treatment. <i>Current Drug Targets</i> , 2015, 16, 209-218.	2.1	16
138	IBS-Symptoms in IBD Patientsâ€™ Manifestation of Concomitant or Different Entities. <i>Journal of Clinical Medicine</i> , 2021, 10, 31.	2.4	16
139	Comparison of antagonist activity of spantide family at human neurokinin receptors measured by aequorin luminescence-based functional calcium assay. <i>Regulatory Peptides</i> , 2005, 131, 23-28.	1.9	15
140	Characterization of the effects of opiorphin and sialorphin and their analogs substituted in position 1 with pyroglutamic acid on motility in the mouse ileum. <i>Journal of Peptide Science</i> , 2013, 19, 166-172.	1.4	15
141	RGS proteins as targets in the treatment of intestinal inflammation and visceral pain: New insights and future perspectives. <i>BioEssays</i> , 2016, 38, 344-354.	2.5	15
142	Anticonvulsant activity of melatonin, but not melatonin receptor agonists Neu-P11 and Neu-P67, in mice. <i>Behavioural Brain Research</i> , 2016, 307, 199-207.	2.2	15
143	Dual Functional Capability of Dendritic Cells â€“ Cytokine-Induced Killer Cells in Improving Side Effects of Colorectal Cancer Therapy. <i>Frontiers in Pharmacology</i> , 2017, 8, 126.	3.5	15
144	Novel selective agonist of GPR18, PSBâ€Kâ€1415 exerts potent antiâ€inflammatory and antiâ€nociceptive activities in animal models of intestinal inflammation and inflammatory pain. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14003.	3.0	15

#	ARTICLE	IF	CITATIONS
145	Biomarkers for early detection of pancreatic cancer – miRNAs as a potential diagnostic and therapeutic tool?. <i>Cancer Biology and Therapy</i> , 2021, 22, 347-356.	3.4	15
146	Emerging treatments in Neurogastroenterology: Perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases. <i>Neurogastroenterology and Motility</i> , 2015, 27, 1057-1068.	3.0	14
147	Highly selective CB2 receptor agonist A836339 has gastroprotective effect on experimentally induced gastric ulcers in mice. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2017, 390, 1015-1027.	3.0	14
148	Alterations of colonic sensitivity and gastric dysmotility after acute cisplatin and granisetron. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13499.	3.0	14
149	Structure-activity Relationship, Conformation and Pharmacology Studies of Morphiceptin Analogues - Selective μ -Opioid Receptor Ligands. <i>Mini-Reviews in Medicinal Chemistry</i> , 2002, 2, 565-572.	2.4	13
150	Novel glycosylated endomorphin-2 analog produces potent centrally-mediated antinociception in mice after peripheral administration. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 6673-6676.	2.2	13
151	Antinociceptive and antidepressant-like action of endomorphin-2 analogs with proline surrogates in position 2. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 4803-4809.	3.0	13
152	Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 771.	2.0	13
153	Chronic abdominal pain in irritable bowel syndrome – current and future therapies. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 729-739.	3.1	13
154	The role of adipose tissue in the pathogenesis of Crohn's disease. <i>Pharmacological Reports</i> , 2019, 71, 105-111.	3.3	13
155	Characterization of the [125I]endomorphin-2 binding sites in the MCF7 breast cancer cell line. <i>Peptides</i> , 2005, 26, 295-299.	2.4	12
156	Novel endomorphin analogues with antagonist activity at the μ -opioid receptor in the gastrointestinal tract. <i>Regulatory Peptides</i> , 2010, 162, 109-114.	1.9	12
157	Is insulin-like growth factor 1 (IGF-1) system an attractive target inflammatory bowel diseases? Benefits and limitation of potential therapy. <i>Pharmacological Reports</i> , 2016, 68, 809-815.	3.3	12
158	G protein-coupled receptor 55 (GPR55) expresses differently in patients with Crohn's disease and ulcerative colitis. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 711-715.	1.5	12
159	Cannabinoids as gastrointestinal anti-inflammatory drugs. <i>Neurogastroenterology and Motility</i> , 2017, 29, e13038.	3.0	12
160	Genetic Molecular Subtypes in Optimizing Personalized Therapy for Metastatic Colorectal Cancer. <i>Current Drug Targets</i> , 2018, 19, 1731-1737.	2.1	12
161	Evaluation of Melatonin Secretion and Metabolism Exponents in Patients with Ulcerative and Lymphocytic Colitis. <i>Molecules</i> , 2018, 23, 272.	3.8	12
162	Organometallic Compounds and Metal Complexes in Current and Future Treatments of Inflammatory Bowel Disease and Colorectal Cancer – a Critical Review. <i>Biomolecules</i> , 2019, 9, 398.	4.0	12

#	ARTICLE	IF	CITATIONS
163	Desensitization of transient receptor potential vanilloid type-1 (TRPV1) channel as promising therapy of irritable bowel syndrome: characterization of the action of palvanil in the mouse gastrointestinal tract. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2020, 393, 1357-1364.	3.0	12
164	Activation of Free Fatty Acid Receptor 4 Affects Intestinal Inflammation and Improves Colon Permeability in Mice. <i>Nutrients</i> , 2021, 13, 2716.	4.1	12
165	Novel endomorphin-2 analogs with mu-opioid receptor antagonist activity. <i>Chemical Biology and Drug Design</i> , 2005, 66, 125-131.	1.1	11
166	Novel highly potent μ -opioid receptor antagonist based on endomorphin-2 structure. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 1350-1353.	2.2	11
167	[Dmt1, d-1-Nal3]morphiceptin, a novel opioid peptide analog with high analgesic activity. <i>Peptides</i> , 2008, 29, 633-638.	2.4	11
168	New neostigmine-based behavioral mouse model of abdominal pain. <i>Pharmacological Reports</i> , 2012, 64, 1146-1154.	3.3	11
169	The role of AST-120 and protein-bound uremic toxins in irritable bowel syndrome: a therapeutic perspective. <i>Therapeutic Advances in Gastroenterology</i> , 2015, 8, 278-284.	3.2	11
170	Elevated risk of venous thromboembolic events in patients with inflammatory myopathies. <i>Vascular Health and Risk Management</i> , 2016, 12, 233.	2.3	11
171	Mixed MOP/DOP agonist biphalin elicits anti-transit effect in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms. <i>Pharmacological Reports</i> , 2016, 68, 32-36.	3.3	11
172	Inhibition of nuclear factor-kappaB, cyclooxygenase-2, and metalloproteinase-9 expression by flavanols from evening primrose (<i>Oenothera paradoxa</i>) in human colon cancer SW-480 cells. <i>Journal of Functional Foods</i> , 2017, 37, 553-563.	3.4	11
173	Gut microbiota: what is its place in pharmacology?. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 921-930.	3.1	11
174	Enkephalinase inhibitors, potential therapeutics for the future treatment of diarrhea predominant functional gastrointestinal disorders. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13526.	3.0	11
175	Blockade of fructose transporter protein GLUT5 inhibits proliferation of colon cancer cells: proof of concept for a new class of anti-tumor therapeutics. <i>Pharmacological Reports</i> , 2021, 73, 939-945.	3.3	11
176	Platelet Activity in the Pathophysiology of Inflammatory Bowel Diseases. <i>Current Drug Targets</i> , 2015, 16, 219-225.	2.1	11
177	Relamorelin and other ghrelin receptor agonists - future options for gastroparesis, functional dyspepsia and proton pump inhibitors-resistant non-erosive reflux disease. <i>Journal of Physiology and Pharmacology</i> , 2017, 68, 797-805.	1.1	11
178	Effect of potent endomorphin degradation blockers on analgesic and antidepressant-like responses in mice. <i>Neuropharmacology</i> , 2011, 61, 1229-1238.	4.1	10
179	Differential effects of salvinorin A on endotoxin-induced hypermotility and neurogenic ion transport in mouse ileum. <i>Neurogastroenterology and Motility</i> , 2011, 23, 583-e212.	3.0	10
180	Synthesis and biological evaluation of new salvinorin A analogues incorporating natural amino acids. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 160-163.	2.2	10

#	ARTICLE	IF	CITATIONS
181	Targeting fatty acid amide hydrolase and transient receptor potential vanilloid 1 simultaneously to modulate colonic motility and visceral sensation in the mouse: A pharmacological intervention with N-arachidonoylserotonin (<sc>AA</sc> <sc>HT</sc>). <i>Neurogastroenterology and Motility</i> , 2017, 29, e13148.	3.0	10
182	Circadian rhythm abnormalities in patients with inflammatory bowel disease – association with adipokine profile. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 294-300.	1.5	10
183	AdipoRon, an Orally Active, Synthetic Agonist of AdipoR1 and AdipoR2 Receptors Has Gastroprotective Effect in Experimentally Induced Gastric Ulcers in Mice. <i>Molecules</i> , 2021, 26, 2946.	3.8	10
184	Sleep disturbance and disease activity in adult patients with inflammatory bowel diseases. <i>Journal of Physiology and Pharmacology</i> , 2018, 69, .	1.1	10
185	Binding of the new morphiceptin analogs to human MCF-7 breast cancer cells and their effect on growth. <i>Regulatory Peptides</i> , 2004, 120, 237-241.	1.9	9
186	The mu-opioid receptor-selective peptide antagonists, antanal-1 and antanal-2, produce anticonvulsant effects in mice. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 40, 126-131.	4.8	9
187	Methyl-orvinolol – Dual activity opioid receptor ligand inhibits gastrointestinal transit and alleviates abdominal pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome. <i>Pharmacological Reports</i> , 2017, 69, 350-357.	3.3	9
188	Alterations in the gut barrier and involvement of Toll-like receptor 4 in murine postoperative ileus. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13286.	3.0	9
189	Alanine scan of sialorphin and its hybrids with opiorphin: synthesis, molecular modelling and effect on enkephalins degradation. <i>Amino Acids</i> , 2018, 50, 1083-1088.	2.7	9
190	The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome. <i>European Journal of Pharmacology</i> , 2018, 836, 34-43.	3.5	9
191	Recent advances in the pharmacological management of constipation predominant irritable bowel syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 73-84.	1.8	9
192	Recent advances in inflammatory bowel disease therapy. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 155, 105550.	4.0	9
193	Pharmacological Properties of Novel Cyclic Pentapeptides with μ -opioid Receptor Agonist Activity. <i>Medicinal Chemistry</i> , 2014, 10, 154-161.	1.5	9
194	The association of the quality of sleep with proinflammatory cytokine profile in inflammatory bowel disease patients. <i>Pharmacological Reports</i> , 2021, 73, 1660-1669.	3.3	9
195	Synthesis of novel morphiceptin analogues modified in position 3 and their binding to μ -opioid receptors in experimental mammary adenocarcinoma. <i>Bioorganic and Medicinal Chemistry</i> , 2003, 11, 3855-3860.	3.0	8
196	Kinetic studies of novel inhibitors of endomorphin degrading enzymes. <i>Medicinal Chemistry Research</i> , 2012, 21, 1445-1450.	2.4	8
197	What is the Future of the Gut Microbiota-Related Treatment? Toward Modulation of Microbiota in Preventive and Therapeutic Medicine. <i>Frontiers in Medicine</i> , 2014, 1, 19.	2.6	8
198	Role of G Protein-coupled Orphan Receptors in Intestinal Inflammation. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 666-673.	1.9	8

#	ARTICLE	IF	CITATIONS
199	Antinociceptive potency of a fluorinated cyclopeptide Dmt-c[D-Lys-Phe- <i>p</i> -CF ₃ -Phe-Asp]NH ₂ . Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 560-566.	5.2	8
200	FABP4 blocker attenuates colonic hypomotility and modulates white adipose tissue-derived hormone levels in mouse models mimicking constipation-predominant IBS.	3.0	8
201	High activity of endogenous opioid system protects against gastric damage development in mouse models of gastric mucosal injury. Pharmacological Reports, 2019, 71, 218-224.	3.3	8
202	New Class of Anti-Inflammatory Therapeutics Based on Gold (III) Complexes in Intestinal Inflammation—Proof of Concept Based on In Vitro and In Vivo Studies. International Journal of Molecular Sciences, 2021, 22, 3121.	4.1	8
203	Oxidative Stress Does Not Influence Subjective Pain Sensation in Inflammatory Bowel Disease Patients. Antioxidants, 2021, 10, 1237.	5.1	8
204	Inflammatory bowel diseases and reproductive health. Pharmacological Reports, 2016, 68, 859-864.	3.3	7
205	The influence of family pattern abnormalities in the early stages of life on the course of inflammatory bowel diseases. Pharmacological Reports, 2016, 68, 852-858.	3.3	7
206	Neuropharmacological characterization of the oneirogenic Mexican plant Calea zacatechichi aqueous extract in mice. Metabolic Brain Disease, 2016, 31, 631-641.	2.9	7
207	Antinociceptive potency of enkephalins and enkephalinase inhibitors in the mouse model of colorectal distension—proof of concept. Chemical Biology and Drug Design, 2018, 92, 1387-1392.	3.2	7
208	Changes in the diet composition of fatty acids and fiber affect the lower gastrointestinal motility but have no impact on cardiovascular parameters: In vivo and in vitro studies. Neurogastroenterology and Motility, 2019, 31, e13651.	3.0	7
209	Free Fatty Acid Receptors as New Potential Targets in Colorectal Cancer. Current Drug Targets, 2020, 21, 1397-1404.	2.1	7
210	Spent hops (<i>Humulus Lupulus</i> L.) extract as modulator of the inflammatory response in lipopolysaccharide stimulated RAW 264.7 macrophages. Journal of Physiology and Pharmacology, 2020, 71, .	1.1	7
211	Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation. World Journal of Gastroenterology, 2015, 21, 7436.	3.3	7
212	Positive allosteric modulation of endogenous delta opioid receptor signaling in the enteric nervous system is a potential treatment for gastrointestinal motility disorders. American Journal of Physiology - Renal Physiology, 2022, 322, G66-G78.	3.4	7
213	Characterization of Specific Signatures of the Oral Cavity, Sputum, and Ileum Microbiota in Patients With Crohn's Disease. Frontiers in Cellular and Infection Microbiology, 2022, 12, 864944.	3.9	7
214	Î¼-Opioid Receptor Ligands Lack Receptor Subtype Selectivity in the Aequorin Luminescence-based Calcium Assay. Chemical Biology and Drug Design, 2007, 70, 247-253.	3.2	6
215	The Novel Endomorphin Degradation Blockers Tyr-Pro-D-CIPhe-Phe-NH ₂ (EMDB1) and Tyr-Pro-Ala-NH ₂ (EMDB2) Prolong Endomorphin ₂ Action in Rat Ileum <i>In Vitro</i> .	3.2	6
216	Acid loading stimulates rat glomerular mesangial cells proliferation through Na ⁺ -H ⁺ exchanger isoform 1 (NHE1)-dependent pathway. Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386, 563-569.	3.0	6

#	ARTICLE	IF	CITATIONS
217	Cannabinoids and Effects on the Gastrointestinal Tract: A Focus on Motility. , 2017, , 947-957.		6
218	Diagnostic value of chemerin in lower gastrointestinal diseasesâ€”a review. Peptides, 2018, 108, 19-24.	2.4	6
219	1-Substituted sialorphin analoguesâ€”synthesis, molecular modelling and in vitro effect on enkephalins degradation by NEP. Amino Acids, 2019, 51, 1201-1207.	2.7	6
220	Cyclic derivative of morphiceptin Dmt-cyclo-(D-Lys-Phe-D-Pro-Asp)-NH ₂ (P-317), a mixed agonist of MOP and KOP opioid receptors, exerts anti-inflammatory and anti-tumor activity in colitis and colitis-associated colorectal cancer in mice. European Journal of Pharmacology, 2020, 885, 173463.	3.5	6
221	Anti-Inflammatory Effect of Homo- and Heterodimers of Natural Enkephalinase Inhibitors in Experimental Colitis in Mice. Molecules, 2020, 25, 5820.	3.8	6
222	Air Pollution Associates with Cancer Incidences in Poland. Applied Sciences (Switzerland), 2020, 10, 7489.	2.5	6
223	Gastrointestinal Adverse Events of Cannabinoid 1 Receptor Inverse Agonists suggest their Potential Use in Irritable Bowel Syndrome with Constipation: A Systematic Review and Meta-Analysis. Journal of Gastrointestinal and Liver Diseases, 2019, 28, 473-481.	0.9	6
224	Silver and Other Metals in the Treatment of Gastrointestinal Diseases. Current Medicinal Chemistry, 2015, 22, 3695-3706.	2.4	6
225	Review: The Role of MOP and DOP Receptors in Treatment of Diarrheapredominant Irritable Bowel Syndrome. Mini-Reviews in Medicinal Chemistry, 2016, 16, 1462-1469.	2.4	6
226	The effect of long-term melatonin supplementation on psychosomatic disorders in postmenopausal women. Journal of Physiology and Pharmacology, 2018, 69, .	1.1	6
227	Nociceptin effect on intestinal motility depends on opioid-receptor like-1 receptors and nitric oxide synthase co-localization. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2015, 6, 73.	1.1	6
228	[³⁵ S]GTPÎ³S binding stimulated by endomorphin-2 and morphiceptin analogs. Biochemical and Biophysical Research Communications, 2006, 345, 162-168.	2.1	5
229	Current overview of colitis-associated colorectal cancer. Open Life Sciences, 2014, 9, 1022-1029.	1.4	5
230	The effect of opioid agonists and antagonists on gastrointestinal motility in mice selected for high and low swim stressâ€”induced analgesia. Neurogastroenterology and Motility, 2016, 28, 175-185.	3.0	5
231	Cannabis and Cannabinoids and the Effects on Gastrointestinal Function: An Overview. , 2017, , 471-480.		5
232	Enkephalin degradation in serum of patients with inflammatory bowel diseases. Pharmacological Reports, 2019, 71, 42-47.	3.3	5
233	Expression of FFAR3 and FFAR4 Is Increased in Gastroesophageal Reflux Disease. Journal of Clinical Medicine, 2020, 9, 4111.	2.4	5
234	Anti-inflammatory and antibacterial effects of human cathelicidin active fragment KR-12 in the mouse models of colitis: a novel potential therapy of inflammatory bowel diseases. Pharmacological Reports, 2021, 73, 163-171.	3.3	5

#	ARTICLE	IF	CITATIONS
235	Prevention and Therapeutic Strategies of Thromboembolic Events in Patients with Inflammatory Bowel Diseases: A Report of Three Cases. <i>Current Drug Targets</i> , 2015, 16, 194-198.	2.1	5
236	Biomarkers for Early Detection of Colitis-associated Colorectal Cancer - Current Concepts, Future Trends. <i>Current Drug Targets</i> , 2020, 22, 137-145.	2.1	5
237	Modulation of the endocannabinoid system by the fatty acid amide hydrolase, monoacylglycerol and diacylglycerol lipase inhibitors as an attractive target for secretory diarrhoea therapy. <i>Journal of Physiology and Pharmacology</i> , 2017, 68, 591-596.	1.1	5
238	The place of tachykinin NK2 receptor antagonists in the treatment diarrhea-predominant irritable bowel syndrome. <i>Journal of Physiology and Pharmacology</i> , 2019, 70, .	1.1	5
239	[d-1-Nal4]endomorphin-2 is a potent μ -opioid receptor antagonist in the aequorin luminescence-based calcium assay. <i>Life Sciences</i> , 2006, 79, 1094-1099.	4.3	4
240	OPIOID ANTAGONIST-INDUCED REGULATION OF THE μ -OPIOID RECEPTOR EXPRESSION IN MCF-7 BREAST CANCER CELL LINE. <i>Endocrine Regulations</i> , 2009, 43, 23-28.	1.3	4
241	Inflammatory bowel disease treatment. <i>Pharmacological Reports</i> , 2016, 68, 787-788.	3.3	4
242	Development of the rectal dosage form with silver-coated glass beads for local-action applications in lower sections of the gastrointestinal tract. <i>Pharmaceutical Development and Technology</i> , 2018, 23, 295-300.	2.4	4
243	Dietary fatty acid content influences the expression of genes involved in the lipid turnover and inflammation in mouse colon and spleen. <i>Pharmacological Reports</i> , 2019, 71, 899-908.	3.3	4
244	Chain length of dietary fatty acids determines gastrointestinal motility and visceromotor function in mice in a fatty acid binding protein 4-dependent manner. <i>European Journal of Nutrition</i> , 2020, 59, 2481-2496.	3.9	4
245	Nrf2 transcriptional activity in the mouse affects the physiological response to tribromoethanol. <i>Biomedicine and Pharmacotherapy</i> , 2020, 128, 110317.	5.6	4
246	Changes in Fatty Acid Dietary Profile Affect the Brain-Gut Axis Functions of Healthy Young Adult Rats in a Sex-Dependent Manner. <i>Nutrients</i> , 2021, 13, 1864.	4.1	4
247	Current Overview on the Use of Mesenchymal Stem Cells for Perianal Fistula Treatment in Patients with Crohn's Disease. <i>Life</i> , 2021, 11, 1133.	2.4	4
248	Effect of cerebral ventricles perfusion with morphiceptin and Met-enkephalin on trigemino-hypoglossal reflex in rats. <i>Journal of Physiology and Pharmacology</i> , 2002, 53, 741-50.	1.1	4
249	Protease-Activated Receptors - Key Regulators of Inflammatory Bowel Diseases Progression. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 7487-7497.	3.5	4
250	The GPR35 expression pattern is associated with overall survival in male patients with colorectal cancer. <i>Pharmacological Reports</i> , 2022, 74, 709-717.	3.3	4
251	Binding of endomorphin-2 to mu-opioid receptors in experimental mouse mammary adenocarcinoma. <i>Chemical Biology and Drug Design</i> , 2005, 65, 459-464.	1.1	3
252	Identification of Endomorphin-1 and Endomorphin-2 Binding Sites in Human μ -Opioid Receptor by Antisense Oligonucleotide Strategy. <i>Chemical Biology and Drug Design</i> , 2008, 72, 507-512.	3.2	3

#	ARTICLE	IF	CITATIONS
253	Synthesis and opioid activity of novel 6-substituted-6-demethoxy-ethenomorphinans. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 3535-3542.	3.0	3
254	Synthesis and Opioid Activity of Novel 6-ketolevorphanol Derivatives. <i>Medicinal Chemistry</i> , 2013, 9, 1-10.	1.5	3
255	Pharmacology and metabolism of infliximab biosimilars – A new treatment option in inflammatory bowel diseases. <i>Pharmacological Reports</i> , 2016, 68, 797-801.	3.3	3
256	Novel derivatives of 1,2,3-triazole, cannabinoid-1 receptor ligands modulate gastrointestinal motility in mice. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2018, 391, 435-444.	3.0	3
257	Possible application of trefoil factor family peptides in gastroesophageal reflux and Barrett's esophagus. <i>Peptides</i> , 2019, 115, 27-31.	2.4	3
258	Cyclic derivatives of morphiceptin possess anti-transit effect in the gastrointestinal tract and alleviate abdominal pain in mice. <i>Pharmacological Reports</i> , 2020, 72, 314-321.	3.3	3
259	The 25(OH)D3, but Not 1,25(OH)2D3 Levels Are Elevated in IBD Patients Regardless of Vitamin D Supplementation and Do Not Associate with Pain Severity or Frequency. <i>Pharmaceuticals</i> , 2021, 14, 284.	3.8	3
260	Chlorogenic acid reduces inflammation in murine model of acute pancreatitis. <i>Pharmacological Reports</i> , 2021, 73, 1448-1456.	3.3	3
261	Colonic inflammation induces changes in glucose levels through modulation of incretin system. <i>Pharmacological Reports</i> , 2021, 73, 1670-1679.	3.3	3
262	Serum Levels of Chemerin in Patients with Inflammatory Bowel Disease as an Indicator of Anti-TNF Treatment Efficacy. <i>Journal of Clinical Medicine</i> , 2021, 10, 4615.	2.4	3
263	Alopecia areata in patients with inflammatory bowel disease: an overview. <i>Folia Medica Cracoviensia</i> , 2016, 56, 5-12.	0.3	3
264	The Anti-Inflammatory Effect of Acidic Mammalian Chitinase Inhibitor OAT-177 in DSS-Induced Mouse Model of Colitis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2159.	4.1	3
265	Measurement of Silver Nanolayer Absorption by the Body in an in Vivo Model of Inflammatory Gastrointestinal Diseases. <i>Metrology and Measurement Systems</i> , 2016, 23, 133-142.	1.4	2
266	Young GI angle: The role of bibliometrics in scientist's career development. <i>United European Gastroenterology Journal</i> , 2017, 5, 1151-1152.	3.8	2
267	What role do cannabinoids have in modern medicine as gastrointestinal anti-inflammatory drugs?. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1931-1934.	1.8	2
268	Adipocyte Fatty Acid Binding Protein (A-FABP) as a Potential New Therapeutic Target for the Treatment of Obesity - Associated Cancers. <i>Current Drug Targets</i> , 2022, 23, 597-605.	2.1	2
269	Evaluation of the effect of liposomes loaded with chlorogenic acid in treatment of 2,4,6-trinitrobenzenesulfonic acid-induced murine colitis. <i>Journal of Physiology and Pharmacology</i> , 2019, 70, .	1.1	2
270	Biologic Therapy in Crohn's Disease – What We Have Learnt So Far. <i>Current Drug Targets</i> , 2020, 21, 792-806.	2.1	2

#	ARTICLE	IF	CITATIONS
271	Inflammatory Bowel Disease – From Bench to Bedside. <i>Current Drug Targets</i> , 2020, 21, 1396-1396.	2.1	2
272	Characterization of the Synergistic Effect between Ligands of Opioid and Free Fatty Acid Receptors in the Mouse Model of Colitis. <i>Molecules</i> , 2021, 26, 6827.	3.8	2
273	Rhenium-coated glass beads for intracolonic administration attenuate TNBS-induced colitis in mice: Proof-of-Concept Study. <i>Folia Medica Cracoviensia</i> , 2015, 55, 49-57.	0.3	2
274	Association between brain-derived neurotrophic factor and symptoms of insomnia and depression in inflammatory bowel disease (IBD) patients. <i>European Psychiatry</i> , 2021, 64, S554-S554.	0.2	2
275	The Involvement of the Endogenous Opioid System in the Gastrointestinal Aging in Mice and Humans. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3565.	4.1	2
276	High activity of the endogenous opioid system and acute but not chronic stress influence experimental colitis development in mice. <i>Journal of Physiology and Pharmacology</i> , 2018, 69, .	1.1	2
277	Japanese quince (<i>Chaenomeles japonica</i>) leaf phenol extract as modulator of the inflammatory response in lipopolysaccharide-triggered murine macrophage RAW 264.7 cells. <i>Journal of Physiology and Pharmacology</i> , 2020, 71, .	1.1	2
278	Current approach to hepatobiliary manifestations in inflammatory bowel disease.. <i>Journal of Physiology and Pharmacology</i> , 2021, 72, .	1.1	2
279	P071 G protein-coupled receptor 30 expression in inflammatory bowel disease patients. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S92.	1.3	1
280	Comment on Choi <i>et al.</i> : High-fat diet decreases energy expenditure and expression of genes controlling lipid metabolism, mitochondrial function and skeletal system development in the adipose tissue, along with increased expression of extracellular matrix remodelling- and inflammation-related genes. <i>British Journal of Nutrition</i> , 2015, 114, 497-498.	2.3	1
281	The past, present and future of gastroenterology in Europe and worldwide. <i>United European Gastroenterology Journal</i> , 2015, 3, 217-217.	3.8	1
282	Cannabinoids Regulate Intestinal Motor Function and Electrophysiological Activity of Myocytes in Rodents. <i>Archives of Medical Research</i> , 2015, 46, 439-447.	3.3	1
283	The Role of Oxidative Stress in the Pathophysiology of Gastrointestinal Disorders. , 2017, , 53-64.		1
284	Prosecretory effect of loperamide in ileal and colonic mucosae of mice displaying high or low swim stress-induced analgesia associated with high and low endogenous opioid system activity. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13166.	3.0	1
285	Traditional Chinese Medicine Da-Cheng-Qi-Tang Ameliorates Impaired Gastrointestinal Motility and Intestinal Inflammatory Response in a Mouse Model of Postoperative Ileus. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-12.	1.2	1
286	Visualization of Estrogen Receptors in Colons of Mice with TNBS-Induced Crohn's Disease using Immunofluorescence. <i>Journal of Visualized Experiments</i> , 2020, , .	0.3	1
287	The age-related alterations in the enteric nervous system and their impact on peristalsis of the gastrointestinal tract. <i>Postepy Biochemii</i> , 2021, 67, 34-43.	0.2	1
288	Critical interactions between opioid and cannabinoid receptors during tolerance and physical dependence development to opioids in the murine gastrointestinal tract: proof of concept. <i>Pharmacological Reports</i> , 2021, 73, 1147-1154.	3.3	1

#	ARTICLE	IF	CITATIONS
289	Ghee Butter from Bovine Colostrum Reduces Inflammation in the Mouse Model of Acute Pancreatitis with Potential Involvement of Free Fatty Acid Receptors. <i>Nutrients</i> , 2021, 13, 3271.	4.1	1
290	Assessment of dietary habits in inflammatory bowel disease patients: A cross-sectional study from Poland. <i>Nutrition Bulletin</i> , 2021, 46, 432-442.	1.8	1
291	Single Nucleotide Polymorphisms in Colitis-Associated Colorectal Cancer: A Current Overview with Emphasis on the Role of the Associated Genes Products. <i>Current Drug Targets</i> , 2020, 21, 1456-1462.	2.1	1
292	Mast Cells Tryptase Promotes Intestinal Fibrosis in Natural Decellularized Intestinal Scaffolds. <i>Tissue Engineering and Regenerative Medicine</i> , 2022, 19, 717-726.	3.7	1
293	Oxygen Binding by Co(II) Complexes with Oxime-Containing Schiff Bases in Solution. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5492.	4.1	1
294	Characterization of Tachykinin-related Peptides from Different Insect Species on Drosophila Tachykinin Receptor-expressing Cell Line. <i>Chemical Biology and Drug Design</i> , 2006, 68, 284-286.	3.2	0
295	Structural comparison of endomorphin-2 and its conformationally restricted analog. <i>Open Chemistry</i> , 2012, 10, 172-179.	1.9	0
296	Comment on "Intestinal Inflammation Modulates Expression of the Iron-Regulating Hormone Hepcidin Depending on Erythropoietic Activity and the Commensal Microbiota". <i>Journal of Immunology</i> , 2014, 193, 5763.1-5763.	0.8	0
297	Cross-talk between serotonin and cannabinoid signaling in the gut, new insights and future perspectives. <i>Pain</i> , 2014, 155, 2204-2205.	4.2	0
298	Editorial (Thematic Issue: The Link between Cardiovascular and Circulatory Events in Inflammatory) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50</i>	2.1	0
299	PhDs in academic gastroenterology: key to a successful career. <i>United European Gastroenterology Journal</i> , 2016, 4, 479-480.	3.8	0
300	Young GI angle: My biggest (career) mistake. <i>United European Gastroenterology Journal</i> , 2018, 6, 1278-1279.	3.8	0
301	P706 Patient knowledge towards biological treatment in inflammatory bowel diseases: a cross-sectional survey. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S474-S474.	1.3	0
302	Endocannabinoid System. , 2020, , 159-166.		0
303	On the Way to Improve Diagnostic Marker Panel for Acute Appendicitis in Adults: the Role of Calprotectin. <i>Indian Journal of Surgery</i> , 0, , 1.	0.3	0
304	Response to lubiprostone in chronic constipation is associated with increased mucus and mucin output: a randomized clinical trial. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 263-264.	0.9	0
305	Psychological stress " does it affect wound healing?. <i>Forum Leczenia Ran</i> , 2020, 2, 95-101.	0.0	0
306	Fatty acids from natural resources in inflammatory gastrointestinal diseases with specific focus on inflammatory bowel disease. , 2022, , 121-135.		0

#	ARTICLE	IF	CITATIONS
307	Comparison of the efficacy of available statistical methods for prediction of the hospitalizations number: proof of concept and validation based on the analysis of Polish National Health Fund data in the years 2009-2017. <i>Folia Medica Cracoviensia</i> , 2019, 59, 89-100.	0.3	0
308	Experimental therapies in Irritable Bowel Syndrome. <i>Folia Medica Cracoviensia</i> , 2021, 61, 5-17.	0.3	0